[Content Courtesy: FOX59] 
LEBANON, Ind. — Officials with Eli Lilly and Company announced an additional $4.5 billion investment in two of its three sites in Lebanon on Wednesday, May 6th.
According to a news release from the company, this brings the company’s total Indiana capital expansion commitments to more than $21 billion since 2020.
Officials expect the Lebanon investment to incorporate new process designs and technologies at Lilly Lebanon API, as well as the opening of Lilly Lebanon Advanced Therapies, the company’s first dedicated genetic medicine manufacturing facility, which opened on Wednesday.
This comes after the company announced plans in 2024 to make both Zepbound and Mounjaro products at its Lebanon API site, according to the release. The investment also will bring the production of Foundayo and retatrutide to Lebanon.
The Lebanon API site is scheduled to open in 2027 and is expected to be the largest API production site in U.S. history, according to company officials.
The release said that Lilly Lebanon Advanced Therapies, a site designed to “support both clinical and commercial production of advanced therapies that target disease at the genetic level,” will be one of three planned sites on the Lebanon campus, including the Lilly Lebanon API site and the Lilly Medicine Foundry.
Recent Comments